Resolution of the Expert council on current issues of prescribing clotting factor VIII with prolonged half-life (INN — Efmoroctocog alfa) in patients with hemophilia A-Reference-Cited by-同舟云学术

Resolution of the Expert council on current issues of prescribing clotting factor VIII with prolonged half-life (INN — Efmoroctocog alfa) in patients with hemophilia A

Published:2021-07-12 Issue:2 Volume:8 Page:142-143
ISSN:2413-5496
Container-title:Russian Journal of Pediatric Hematology and Oncology
language:
Short-container-title:Ross. ž. det. gematol. onkol.

Author:

Editorial Article

Abstract

В ходе Совета экспертов, который состоялся 11 мая 2021 г., обсуждались критерии назначения препарата фактора свертывания крови VIII (эфмороктоког альфа) с пролонгированным периодом полувыведения пациентам с гемофилией А.

Publisher

OOO Grafika

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Reference8 articles.

1. Instructions for the medical use of the drug Eloctate (Efmoroctocog alpha) LP-006034. [Electronic resource]: https://grls.rosminzdrav.ru/GRLS.aspx (appeal date 17.08.2020). (In Russ.).

2. McCue J., Kshirsagar R., Selvitelli K., Lu Q., Zhang M., Mei B., Peters R., Pierce G.F., Dumont J., Raso S., Reichert H. Manufacturing process used to produce long-acting recombinant factor VIII Fc fusion protein. Biologicals 2015;43(4):213-9. doi: 10.1016/j.biologicals.2015.05.012.

3. Rath T., Baker K., Dumont J.A., Peters R.T., Jiang H., Qiao S.-W., Lencer W.I., Pierce G.F., Blumberg R.S. Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics. Crit Rev Biotechnol 2015;35(2):235-54. doi: 10.3109/07388551.2013.834293.

4. Powell J.S., Josephson N.C., Quon D., Ragni M.V., Cheng G., Li E., Jiang H., Li L., Dumont J.A., Goyal J., Zhang X., Sommer J., McCue J., Barbetti M., Luk A., Pierce G.F. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in haemophilia A patients. Blood 2012;119(13):3031-7. doi: 10.1182/blood-2011-09-382846.

5. Young G., Mahlangu J., Kulkarni R., Nolan B., Liesner R., Pasi J., Barnes C., Neelakantan S., Gambino G., Cristiano L.M., Pierce G.F., Allen G. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A. J Thromb Haemost 2015;13(6):967-77. doi: 10.1111/jth.12911.